Objective:To explore the clinical effect of vinorelbine and paclitaxel combined chemotherapy containing cisplatin for treatment of advanced non-smal cel lung cancer.Methods:64 cases of advanced non-smal cel lung cancer from 2012 to 2016 were selected and divided into observation group and control group randomly.The cases in observation group were taken paclitaxel combined cisplatin chemotherapy (TP chemotherapy).The cases in control group were taken vinorelbine combined cisplatin chemo-therapy (NP chemotherapy).After 2 cycles of chemotherapy,the clinical effect,complications and intergroup difference of the two groups were compared.Results:there was no significant difference of response rate,complete remission,1-year survival rates and median survival time between the two groups (P>0.05).The complicants included nausea,emesis,leucopenia and weak.The incidence of adverse reactions in observation group was lower than control group (P<0.05).Conclusion:there was no obvious difference of short-term effects between TP chemotherapy and NP chemotherapy for treatment of advanced non-smal cel lung cancer.But TP chemotherapy has less com-plication and is wel tolerated.%目的：：探讨长春瑞滨、紫杉醇分别与顺铂联合的化疗方案治疗晚期非小细胞肺癌的临床疗效.方法：选择我院2012年至2016年间的64例晚期非小细胞肺癌患者，随机分为观察组与对照组，每组32例，观察组采用紫杉醇与顺铂联合的化疗方案(TP 方案)，对照组采用长春瑞滨与顺铂联合的化疗方案(NP 方案)，化疗至少2个周期后，评价两组疗效和不良反应情况，并进行组间对比分析.结果：两组化疗有效率、完全缓解率、1年生存率、中位生存期均无明显差异(P＞0．05).两组化疗不良反应主要包括恶心呕吐、白细胞减少、乏力等，两组患者在不良反应发生率方面存在统计学差异，观察组不良反应发生率低于对照组(P＜0．05).结论：TP 方案与 NP 方案治疗晚期非小细胞肺癌的近期疗效无明显差异，但 TP 方案不良反应较少，患者耐受性相对较好.
展开▼
